Financial News
Pfizer CEO reveals 2030 growth plan as company faces up to $18 billion revenue hit from generics
November 01, 2022 at 16:09 PM EDT
CEO Albert Bourla said Pfizer is staring down an expected loss of up to $18 billion in revenue from 2025 through 2030 as patent protections expire.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
